On September 24, 2024, NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, announced two significant developments. Firstly, the company has regained compliance with the NASDAQ Minimum Bid Price Rule, having maintained a closing bid price of $1.00 or more for at least 10 consecutive business days. This achievement closes the prior bid price deficiency matter. Secondly, NeuroSense Therapeutics was granted a key U.S. patent for its novel PrimeC formulation, which is the lead asset in its pipeline for treating ALS (amyotrophic lateral sclerosis) and Alzheimer's disease. The company's CEO, Alon Ben-Noon, expressed satisfaction with regaining NASDAQ compliance and is looking forward to initiating a Phase 3 trial in the U.S. and engaging with potential partners. NeuroSense focuses on developing therapies for neurodegenerative diseases, aiming to address the significant unmet medical needs in this area. The company's strategy involves combined therapies targeting multiple pathways associated with these diseases.

On September 24, 2024, NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, announced two significant developments. Firstly, the company has regained compliance with the NASDAQ Minimum Bid Price Rule, having maintained a closing bid price of $1.00 or more for at least 10 consecutive business days. This achievement closes the prior bid price deficiency matter. Secondly, NeuroSense Therapeutics was granted a key U.S. patent for its novel PrimeC formulation, which is the lead asset in its pipeline for treating ALS (amyotrophic lateral sclerosis) and Alzheimer's disease. The company's CEO, Alon Ben-Noon, expressed satisfaction with regaining NASDAQ compliance and is looking forward to initiating a Phase 3 trial in the U.S. and engaging with potential partners. NeuroSense focuses on developing therapies for neurodegenerative diseases, aiming to address the significant unmet medical needs in this area. The company's strategy involves combined therapies targeting multiple pathways associated with these diseases.